Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

PHAR stock hub

Pharming Group N.V. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

PHARis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

916.9M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

PHAR

In the news

Latest news · PHAR

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E19.5

P25 12.3P50 18.4P75 33.1

Trailing P/E74.2

P25 14.9P50 23.2P75 38.5

ROE5

P25 -105.6P50 -46.5P75 -3.1

ROIC10

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All PHAR market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

239

Groups with data

Currency

USD

Showing 239 of 239 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001828316
Company name	Pharming Group N.V.
Country	Netherlands
Country code	US
Cusip	71716E105
Employees	407
Employees Change	3%
Employees Change Percent	0.74
Enterprise value	$861.8M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US71716E1055
Last refreshed	2026-05-10
Market cap	$916.9M
Market cap category	Small-Cap
Price	$12.98
Price currency	USD
Rev Per Employee	907,830.47x
Sector	Healthcare
Sic	2834
Symbol	PHAR
Website	https://www.pharming.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	1.35%
EV Earnings	69.74x
EV Sales Forward	2.6x
EV/EBIT	24.7x
EV/EBITDA	20.38x
EV/FCF	15.47x
EV/Sales	2.33x
FCF yield	6.08%
Forward P/E	19.47x
P/B ratio	3.41x
P/E ratio	74.2x
P/S ratio	2.48x
PS Forward	2.76x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	9.44%
EBITDA Margin	11.44%
FCF margin	15.08%
Gross margin	88.14%
Gross Profit	$325.7M
Gross Profit Growth	14.12%
Gross Profit Growth Q	-7.02%
Gross Profit Growth3 Y	20.79%
Gross Profit Growth5 Y	12.61%
Net Income	$12.4M
Net Income Growth Quarters	4%
Net Income Growth Years	1%
Net Income Growth5 Y	-19.76%
Pretax Margin	5.38%
Profit Margin	3.34%
Profit Per Employee	$30,361
Profitable Years	1
ROA	4.89
Roa5y	1.24
ROCE	9.25
ROE	5.04
Roe5y	1.21
ROIC	10
Roic5y	1.06

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	44.26%
Cagr3y	4.85%
Cagr5y	-0.34%
EPS Growth Quarters	3
EPS Growth Years	1
EPS Growth5 Y	-22.02
FCF Growth	994.32%
FCF Growth5 Y	-2.9%
OCF Growth	827.48%
OCF Growth Q	741.38%
OCF Growth5 Y	-4.37%
Revenue Growth	15.21x
Revenue Growth Q	-8.4x
Revenue Growth Years	4x
Revenue Growth3 Y	22.39x
Revenue Growth5 Y	12.79x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.83
Assets	$489.4M
Cash	$170.2M
Current Assets	$295.5M
Current Liabilities	$112.3M
Debt	$116.2M
Debt EBITDA	$2.75
Debt Equity	$0.43
Debt FCF	$2.09
Equity	$269M
Interest Coverage	3.25
Liabilities	$220.4M
Long Term Assets	$193.9M
Long Term Liabilities	$108.1M
Net Cash	$54M
Net Cash By Market Cap	$5.89
Net Debt EBITDA	$-1.28
Net Debt Equity	$-0.2
Net Debt FCF	$-0.97
Tangible Book Value	$138M
Tangible Book Value Per Share	$0.19
WACC	5

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.63
Inventory Turnover	0.71
Net Working Capital	$21.1M
Quick ratio	2.05
Working Capital	$183.2M
Working Capital Turnover	$2.31

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-13.48%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	44.22%
200-day SMA	15.59
3Y total return	15.28%
50-day SMA	16.22
50-day SMA vs 200-day SMA	50over200
5Y total return	-1.67%
All Time High	21.99
All Time High Change	-40.97%
All Time High Date	2020-12-23
All Time Low	6.1
All Time Low Change	112.79%
All Time Low Date	2022-06-16
ATR	0.84
Beta	0.12
Ch YTD	-26.54
High	13.09
High52	21.34
High52 Date	2026-01-27
High52ch	-39.18%
Low	12.67
Low52	8.69
Low52 Date	2025-05-16
Low52ch	49.38%
Ma50ch	-19.95%
Premarket Change Percent	6.83
Premarket Price	$12.82
Premarket Volume	1,877
Price vs 200-day SMA	-16.76%
RSI	30.52
RSI Monthly	49.4
RSI Weekly	40.06
Sharpe ratio	0.86x
Sortino ratio	1.31
Total Return	-13.48%
Tr YTD	-26.54
Tr1m	-20.95%
Tr1w	-23.56%
Tr3m	-19.33%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	3
Analyst Count Top	1
Analyst Price Target Top	$37
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$0.01
Earnings Revenue Estimate	92,403,336x
Earnings Revenue Estimate Growth	16.82x
Operating Income	$34.9M
Operating Income Growth	158.9
Operating Income Growth5 Y	-10.75
Operating margin	9.44
Price target	$38.33
Price Target Change	$195
Price Target Change Top	$185

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	695,284,727%
Float Percent	93.36%
Net Borrowing	-16,505,000
Shares Insiders	1.55%
Shares Institutions	22.84%
Shares Out	744,714,285
Shares Qo Q	-1.64%
Shares Yo Y	13.48%
Short Float	0%
Short Ratio	0.4
Short Shares	0

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$41.3M
Average Volume	13,425.2x
Bv Per Share	0.36
CAPEX	$-705,000
Ch1m	-20.95
Ch1w	-23.56
Ch1y	44.22
Ch3m	-19.33
Ch3y	15.28
Ch5y	-1.67
Ch6m	-15.88
Change	8.17%
Change From Open	1.96
Close	12
Days Gap	6.08
Depreciation Amortization	7,393,000
Dollar Volume	253,499.4
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$34.9M
EBITDA	$42.3M
EPS	$0.02
F Score	5
FCF	$55.7M
FCF EV Yield	6.47x
FCF Per Share	$0.07
Financing CF	-1,008,000
Fiscal Year End	December
Founded	1,988
Graham Number	3.8712
Graham Upside	-70.18
Income Tax	$7.7M
Investing CF	-68,199,000
Is Primary Listing	0
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-04-02
Lynch Fair Value	$0.87
Lynch Upside	-93.26
Ma150	16.38
Ma150ch	-20.77%
Ma20	16.47
Ma20ch	-21.18%
Net CF	-7,714,000
Next Earnings Date	2026-07-30
Open	12.73
Optionable	No
P FCF Ratio	16.45
P OCF Ratio	16.25
Position In Range	73.81
Post Close	12.98
Postmarket Change Percent	-1.46
Postmarket Price	$12.79
Ppne	23,098,000
Pre Close	12
Price Date	2026-05-08
Price EBITDA	$21.69
Ptbv Ratio	6.65
Relative Volume	1.45x
Revenue	369,487,000x
SBC By Revenue	3.9x
Share Based Comp	14,415,000
Tax By Revenue	2.08x
Tax Rate	38.57%
Tr6m	-15.88%
Volume	19,530

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does PHAR pay a dividend?

Capital-return profile for this ticker.

Performance

PHAR stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns PHAR?

Insider, institutional, and short-interest positioning.

Institutional ownership

+22.8%

Float: +93.4% of shares outstanding

Insider ownership

+1.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

PHAR momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

30.5

Neutral momentum band

Price vs 200-day MA

-16.8%

50/200-day relationship not available

Beta (5Y)

0.12

Less volatile than the market

Sharpe ratio

0.86

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About PHAR

Hub-level FAQ points readers to the deeper analysis pages.

What is the current PHAR stock rating?

Pharming Group N.V. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full PHAR analysis?

The full report lives at /stocks/PHAR/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for PHAR?

The latest report frames PHAR around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the PHAR page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.